Clinical and polygraphic effects of d.1 5 HTP on narcolepsy-cataplexy.
d.1 5 hydroxy-trytophan (600 mg a day) or a placebo were administered during 4 weeks following a double blind cross over design to 11 narcoleptic-cataplectic patients. Daily number of cataplectic and narcoleptic attacks did not vary. The 36 hours polygraphic recordings performed at the end of each treatment exhibit: a trend toward a decrease of the duration of the day time sleep and a significant increase of the duration of the night sleep.
D006916:5-Hydroxytryptophan / Q000008:administration & dosage / Q000627:therapeutic use*; D002385:Cataplexy / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D008297:Male; D009290:Narcolepsy / Q000188:drug therapy*; D010919:Placebos; D012890:Sleep / Q000187:drug effects; D012894:Sleep Stages / Q000187:drug effects
D010919:Placebos; D006916:5-Hydroxytryptophan; D007099:Imipramine